Bilirubin, Direct

Bilirubin, Direct (conjugated bilirubin) is used to assess liver and biliary tract disease and to classify jaundice by distinguishing conjugated from unconjugated hyperbilirubinemia. Increased direct bilirubin is associated with intrahepatic and extrahepatic cholestasis, hepatocellular disorders such as hepatitis, cirrhosis, and advanced neoplasia, cholestatic drug reactions, and hereditary conjugated hyperbilirubinemias including Dubin–Johnson and Rotor syndromes. When ordered with total and indirect (unconjugated) bilirubin, this test supports the differential diagnosis of neonatal jaundice and evaluation of risk for bilirubin encephalopathy, investigation of impaired bile flow, and longitudinal monitoring in patients with liver or biliary disease or those receiving potentially hepatotoxic or hemolytic medications.

Bilirubin derives from heme catabolism during routine erythrocyte turnover. The unconjugated (indirect) fraction circulates tightly bound to albumin and is delivered to the liver, where uridine diphosphate–glucuronyltransferase conjugates it with glucuronic acid to produce the water‑soluble conjugated (direct) fraction. In diazo reactions historically used to define these fractions, conjugated bilirubin reacts in aqueous solution without accelerators, whereas unconjugated bilirubin requires accelerants. Interpreting total, direct, and indirect bilirubin together helps distinguish prehepatic (hemolytic), hepatic (parenchymal), and posthepatic (obstructive) causes of jaundice. Obstruction of bile flow leads to accumulation of direct bilirubin in serum; because it is water‑soluble, it is the only fraction excreted by the kidney and may darken urine. Concurrent increases in both fractions suggest hepatocellular dysfunction with impaired uptake and excretion. In neonates, physiologic jaundice commonly reflects increased red cell turnover and limited conjugation capacity, producing elevations in indirect bilirubin. Persistent or marked jaundice warrants evaluation for hemolytic disease, congenital hepatobiliary disorders (including biliary atresia), or neonatal hepatitis, given the neurotoxicity of unconjugated bilirubin.